Drug reaction with eosinophilia and systemic symptoms (DRESS) in children

Francesca Mori; Carlo Caffarelli; Silvia Caimmi; Paolo Bottau; Lucia Liotti; Fabrizio Franceschini; Fabio Cardinale; Roberto Bernardini; Giuseppe Crisafulli; Francesca Saretta; Elio Novembre

doi:10.23750/abm.v90i3-S.8167

Drug reaction with eosinophilia and systemic symptoms (DRESS) in children

Authors

Francesca Mori Allergy Unit, Department of Pediatric Medicine, Anna Meyer Children’s University Hospital, Florence, Italy
Carlo Caffarelli Clinica Pediatrica, Dipartimento di Medicina e Chirurgia, Azienda Ospedaliero-Universitaria, Università di Parma, Italy
Silvia Caimmi Pediatric Clinic, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Paolo Bottau Pediatric and Neonatology Unit, Imola Hospital, Imola (BO), Italy
Lucia Liotti Department of Pediatrics, Senigallia Hospital, Senigallia, Italy
Fabrizio Franceschini UOC Pediatria, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, Italy
Fabio Cardinale UOC di Pediatria, Azienda Ospedaliera-Universitaria “Consorziale-Policlinico”, Ospedale Pediatrico Giovanni XXIII, Bari, Italy
Roberto Bernardini Pediatric Unit, “San Giuseppe” Hospital, Empoli, Italy
Giuseppe Crisafulli UO Allergologia, Dipartimento di Pediatria, Università di Messina, Italy
Francesca Saretta Pediatric Department, AAS2 Bassa Friulana-Isontina, Palmanova-Latisana, Italy; Pediatric Allergy Unit, Department of Medicine, Udine, Italy
Elio Novembre Allergy Unit, Department of Pediatric Medicine, Anna Meyer Children’s University Hospital, Florence, Italy

DOI: https://doi.org/10.23750/abm.v90i3-S.8167

Keywords:

children, drug reaction with eosinophilia and systemic symptoms, severe cutaneous adverse reactions

Abstract

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe reaction to drugs. Incidence of DRESS in children is not well known and the mortality rate seems to be lower than 10%. Anticonvulsants are the main drugs involved both in adults and in children. The treatment of choice is intravenous immunoglobulins and corticosteroids used in synergy. Today there are not controlled clinical trials regarding DRESS treatment in children. Anyway, the prompt withdrawn of the offending drug is of paramount importance for a better prognosis. DRESS sequels may occur, consequently, follow-up visits are required at least until the first year after the reaction.

Downloads

Published

29-01-2019

Issue

Vol. 90 No. 3-S (2019): Advances in pediatric drug allergy - Guest Editor: Carlo Caffarelli

Section

REVIEWS

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

How to Cite

Mori F, Caffarelli C, Caimmi S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) in children. Acta Biomed. 2019;90(3-S):66-79. doi:10.23750/abm.v90i3-S.8167

Download Citation